Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Syros Pharmaceuticals Inc (SYRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8278)・商品コード:DATA904C8278
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:61
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and SY-1365, a potent and selective small molecule inhibitor of CDK7 that is used to treat patients with transcriptionally driven solid tumors and acute leukemias. Syors provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. Its gene control platform identifies novel gene control targets linked to genomically defined patient populations, and drugging gene control targets. The company partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US.

Syros Pharmaceuticals Inc (SYRS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Syros Pharma Raises USD10 Million in Venture Financing 13
Syros Pharma Raises USD40 Million in Venture Financing 14
Syros Pharma Raises USD53 Million in Series B Venture Financing 16
Syros Pharma Raises US$30 Million In Series A Financing 18
LS22 Raises USD1.25 Million in Venture Financing 19
LS22 Raises USD1.3 Million in Venture Financing 20
Partnerships 21
Incyte and Syros Pharma Enter into Agreement 21
Syros Pharma Amends Research Agreement With Multinational Pharmaceutical Company 22
Licensing Agreements 23
Syros Pharma Amends Licensing Agreement with TMRC 23
Syros Pharma Enters into Licensing Agreement with Whitehead Institute 24
Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 25
Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 27
Equity Offering 28
Syros Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD46 Million 28
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 30
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 31
Syros Pharma Plans to Raise Funds through Public Offering of Shares 32
Syros Pharma Raises USD35 Million in Private Placement of Shares 33
Syros Pharma Raises USD57.5 Million in IPO 34
Syros Pharmaceuticals Inc – Key Competitors 36
Syros Pharmaceuticals Inc – Key Employees 37
Syros Pharmaceuticals Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 07, 2018: Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 39
May 10, 2018: Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 41
Mar 12, 2018: Syros Announces Fourth Quarter and Full Year 2017 Financial Results 43
Nov 08, 2017: Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 45
Aug 09, 2017: Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 47
May 15, 2017: Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 49
Mar 20, 2017: Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 51
Corporate Communications 53
Mar 12, 2018: Syros Pharmaceuticals Appoints Joseph J. Ferra As Chief Financial Officer 53
Nov 13, 2017: Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer 54
Jun 12, 2017: Syros Appoints Srinivas Akkaraju to Its Board of Directors 55
Jan 30, 2017: Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors 56
Government and Public Interest 57
Feb 27, 2017: Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference 57
Product News 58
Jun 19, 2017: Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting 58
03/01/2017: Syros to Present New Data on CDK12/13 Inhibitor program at Upcoming AACR Annual Meeting 59
Other Significant Developments 60
Jan 08, 2018: Syros Announces 2018 Strategic Priorities and Expected Milestones 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Syros Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Syros Pharma Raises USD10 Million in Venture Financing 13
Syros Pharma Raises USD40 Million in Venture Financing 14
Syros Pharma Raises USD53 Million in Series B Venture Financing 16
Syros Pharma Raises US$30 Million In Series A Financing 18
LS22 Raises USD1.25 Million in Venture Financing 19
LS22 Raises USD1.3 Million in Venture Financing 20
Incyte and Syros Pharma Enter into Agreement 21
Syros Pharma Amends Research Agreement With Multinational Pharmaceutical Company 22
Syros Pharma Amends Licensing Agreement with TMRC 23
Syros Pharma Enters into Licensing Agreement with Whitehead Institute 24
Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 25
Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 27
Syros Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD46 Million 28
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 30
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 31
Syros Pharma Plans to Raise Funds through Public Offering of Shares 32
Syros Pharma Raises USD35 Million in Private Placement of Shares 33
Syros Pharma Raises USD57.5 Million in IPO 34
Syros Pharmaceuticals Inc, Key Competitors 36
Syros Pharmaceuticals Inc, Key Employees 37
Syros Pharmaceuticals Inc, Subsidiaries 38

List of Figures
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8278)販売に関する免責事項を必ずご確認ください。
★調査レポート[Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆